Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on July 30, 2013. The report details a material definitive agreement entered into on the same date regarding a registered direct offering of common stock.
Key Financial Metrics
- Transaction Type: Registered direct offering of common stock.
- Shares Issued: 2,142,857 shares.
- Price Per Share: $7.00.
- Gross Proceeds: $15,000,000.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these ongoing operational metrics; it only reports the proceeds from this specific capital raise.
Material Changes
The primary material change is the increase in equity capital resulting from the sale of 2,142,857 shares to an accredited investor. This transaction was executed pursuant to a prospectus supplement filed on July 31, 2013, under an effective Form S-3 registration statement.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclosures associated with the securities purchase agreement. The transaction was completed with an accredited investor, and the legality of the issuance was confirmed by legal counsel (Sichenzia Ross Friedman Ference LLP).
Investor Verification Checklist
- Verify the company name discrepancy: The filing is for Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the use of the $15,000,000 gross proceeds as outlined in the attached press release (Exhibit 99.1).
- Review the full Securities Purchase Agreement (Exhibit 10.1) for any lock-up provisions or registration rights.
- Check subsequent filings for the impact of this dilution on existing shareholders.